Adding to Claudin18.2 port­fo­lio, As­traZeneca pays $63M cash for an­ti­body-drug con­ju­gate out of Chi­na

As­traZeneca is slid­ing an­oth­er can­di­date that tar­gets Claudin18.2 in­to its pipeline — and this time it’s go­ing for one that’s al­ready in the clin­ic.

The phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.